Amarin Corp Plcuk (AMRN) Other Gross PP&E Adjustments (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Other Gross PP&E Adjustments of -$6.0 million for Q1 2026, up 28.45% year-over-year from -$4.7 million in Q1 2025, and down 19.86% quarter-over-quarter from -$5.0 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Other Gross PP&E Adjustments (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Other Gross PP&E Adjustments data on file, last reported at -$6.0 million in Q1 2026.
- Other Gross PP&E Adjustments for Q1 2026 came in at -$6.0 million, up 28.45% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.0 million (up 28.45% YoY), and the FY2025 annual result was -$5.0 million, up 17.99% from the prior year.
- Other Gross PP&E Adjustments retreated to -$6.0 million in Q1 2026 per AMRN's latest filing, from -$5.0 million in the prior quarter.
- Over five years, Other Gross PP&E Adjustments peaked at -$5.0 million in Q4 2025 and troughed at -$9.2 million in Q1 2023.
- A 5-year average of -$7.6 million and a median of -$7.9 million in 2024 frame the typical range for Other Gross PP&E Adjustments.
- The sharpest annual moves came in 2022 and 2026: Other Gross PP&E Adjustments slumped 33.38% in 2022, then climbed 28.45% in 2026.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at -$5.8 million in 2022, then retreated by 18.47% to -$6.8 million in 2023, then rose by 10.31% to -$6.1 million in 2024, then gained by 17.99% to -$5.0 million in 2025, then decreased by 19.86% to -$6.0 million in 2026.
- Business Quant data shows AMRN's Other Gross PP&E Adjustments at -$6.0 million in Q1 2026, -$5.0 million in Q4 2025, and -$7.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -941.03 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 49.60 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -2.70 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 8.42 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -1.53 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | -6.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.01 Mn |
| Mar 31, 2026 | -6.01 Mn |
| Dec 31, 2025 | -5.01 Mn |
| Dec 31, 2025 | -5.01 Mn |
| Sep 30, 2025 | -7.20 Mn |
| Sep 30, 2025 | -7.20 Mn |
| Jun 30, 2025 | -7.64 Mn |
| Jun 30, 2025 | -7.64 Mn |
| Mar 31, 2025 | -8.40 Mn |
| Mar 31, 2025 | -8.40 Mn |
| Dec 31, 2024 | -6.11 Mn |
| Dec 31, 2024 | -6.11 Mn |
| Sep 30, 2024 | -7.98 Mn |
| Sep 30, 2024 | -7.98 Mn |
| Jun 30, 2024 | -7.54 Mn |
| Jun 30, 2024 | -7.54 Mn |
| Mar 31, 2024 | -7.90 Mn |
| Mar 31, 2024 | -7.90 Mn |
| Dec 31, 2023 | -6.82 Mn |
| Dec 31, 2023 | -6.82 Mn |